Proposed Agenda & Faculty, July 14-15 2023

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at:

office@md-education.com

MD Education Ltd
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North, Suite 180,
Clearwater, Florida 33762

Paolo Strati, MD

MD Anderson Cancer Center

Paolo Strati MD is currently an Assistant Professor, Term Tenure Track, in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, TX, and previously served as Assistant Professor at the Mayo Clinic, in Rochester (MN).

Dr. Strati earned his medical degree cum laude from the San Raffaele University of Milan (Italy) in 2008, and completed an Internal Medicine Residency at the same institution and, subsequently, at the Mayo Clinic, in Rochester (MN). He also completed a Hematology-Oncology Fellowship at MD Anderson Cancer Center, a Leukemia and Lymphoma fellowship at the same institution, and a Malignant Hematology fellowship at the Barts Cancer Institute, in London (UK).

Dr. Strati is a recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic. He is author of several peer-reviewed manuscripts published on high impact journal, including Blood and Lancet Haematology, and he is regularly invited to present his work at international scientific meetings, including the American Society of Hematology and the American Society of Clinical Oncology conference. In light of his research accomplishments, he has received multiple grants and awards, including a NIH R21 grant, the Lymphoma Research Foundation Career Development Award and the Leukemia Lymphoma Society Career Development Award.

Dr. Strati is committed to gain further insight into the biology of the lymphoma immune microenvironment, and to manipulate its components successfully, in order to develop novel effective therapies and to decrease the toxicity of treatment strategies already available for patients with B-cell lymphoma.

Elizabeth Brem, MD

UCI Health Cancer Center

Dr. Elizabeth Brém is currently a Clinical Associate Professor at the University of California, Irvine, with a clinical focus in lymphomas, CLL, and multiple myeloma. She earned her medical degree from the University of Buffalo summa cum laude with thesis honors and completed her residency in Internal Medicine and fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA. Dr. Brém serves as the chair of the University of California Hematologic Malignancies Consortium Lymphoma/CLL committee and is an active member of ASH, having served on a number of committees and as a former Associate Editor of ASH Clinical News. Dr. Brém is also active in the NCTN and is currently the study chair of SWOG S1918, a study for patients age 75 and older with a new diagnosis of DLBCL. She has participated in a number of high-profile mentoring programs and in 2021 was awarded the Coltman Fellowship from the Hope Foundation to support her efforts on S1918.